The global pharmaceutical market has long been a playground for price discrimination, and Ozempic is the latest exhibit. Reports confirm that Canadian patients are paying significantly less for the blockbuster diabetes drug than their American counterparts. Meanwhile, the UK’s drug pricing watchdog is sharpening its pencils. This is not a story about healthcare compassion. It is a story about market failure, arbitrage, and the taxpayer’s hidden subsidy.
Consider the numbers. In the United States, Ozempic costs around $900 per month. In Canada, the same drug is roughly $300. That is a 200 per cent premium for American patients. Why? Because the US lacks the collective bargaining power of a single-payer system. Pharmaceutical companies set prices at what the market will bear. And the US market bears a lot. The result is a wealth transfer from American wallets to Danish shareholders.
But here is the rub. The UK’s National Institute for Health and Care Excellence (NICE) is now reviewing whether Ozempic offers value for money. The drug’s list price in Britain is around £80 per month, deeply discounted by Novo Nordisk to secure NHS access. Yet even that price is under scrutiny. NICE’s yardstick is cost per quality-adjusted life year. If Ozempic fails that test, the NHS could restrict its use. That would be a rational fiscal decision, but it would also highlight the absurdity of global drug pricing.
Market efficiency demands that prices reflect value. But value is subjective. In the US, obesity and diabetes are epidemic. The demand for Ozempic is inelastic patients will pay almost anything. In the UK, the NHS acts as a monopsonist, driving hard bargains. The gap between the two is not a glitch. It is a feature of a system where the US effectively subsidises global drug development. American consumers bear the innovation tax. The rest of the world free-rides.
Now consider capital flight. If the UK tightens its pricing screws, what happens to Novo Nordisk’s revenue? They will simply pivot to higher-margin markets. The UK accounts for a small fraction of global sales. The real money is in America. So NICE’s review is largely symbolic. It might save the NHS a few million pounds, but it will not change the arithmetic of pharmaceutical investment.
Yet there is a deeper concern. If drug companies perceive that the UK is a hostile environment for pricing, they may delay launches or withhold new products. We have seen this before with hepatitis C cures and cancer treatments. The NHS’s tough stance can lead to rationing by price. The result? British patients wait longer for cutting-edge therapies. That is the hidden cost of fiscal prudence.
Inflation is another complicating factor. The Bank of England is wrestling with sticky price growth, and healthcare costs are a contributing factor. But drug pricing is not the main driver. The real inflation risk comes from energy and labour markets. Still, every pound saved on Ozempic is a pound that can be spent elsewhere. The Treasury will be watching.
Gilt yields have been jittery of late, reflecting concerns about fiscal sustainability. The UK’s debt-to-GDP ratio is elevated. Every line item is under scrutiny. The Ozempic review is a minor skirmish in a larger war over public spending. But it reveals a fundamental truth. The NHS is a pricing bottleneck in a global market. It can hold the line only if it is willing to accept delays and denials.
My verdict? The Ozempic saga is a reminder that drug pricing is a tale of two systems. The American model rewards innovation at the expense of equity. The British model prioritises access at the expense of choice. Neither is perfect. But when Canadians pay half what Americans do for the same molecule, something is broken. The question is whether the UK’s review will fix it or merely expose the cracks.
For investors, the lesson is clear. Pharmaceutical companies with monopoly products will continue to extract maximum value from the US market. The UK is a sideshow. For policymakers, the takeaway is that price controls have consequences. They may save money today, but they risk stifling the pipeline of tomorrow’s drugs. That is a trade-off. And in the cold light of fiscal reality, it is one that must be made with open eyes.
